By Draper
We specialize in designing and developing microfluidic hardware, software and disposable systems tailored to meet the demands of rapidly evolving diagnostics and biomanufacturing tools. In collaboration with industry, Draper has produced advances in biomanufacturing technologies. Draper's engineers created best-in-class hardware for performing key unit bioprocessing operations required for decreasing the cost of manufacture of cancer immunotherapies and improving access to these new lifesaving medicines. Our solutions automate and streamline bioprocessing unit operations and have modular flexibility to adjust for evolving requirements of the manufacturing process, multiple cell types, donor variations, and new payloads. Together with pharma partners as well as sponsorship from FDA, NIH, DARPA and others, our acoustic cell separation technology permits label-free or labelled isolation of cells and pathogens for downstream processing without the need for magnetic beads or antibodies. Additionally, Draper engineered a microfluidic device that improves the co-localization and binding of target cells and viral vectors to deliver higher rates of viral transduction using less vector in a fraction of the time when compared to standard methods using static culture. In collaboration with industry, Draper engineered a continuous-flow electroporation module that uses high-precision microfluidics to tightly control cell exposure to electrical current, increase throughput to 10 billion cells per hour while simultaneously reducing manual touch labor eliminating hours of processing time and cost for cell therapy manufacturing process. Our unique Differential Mobility Spectrometry (DMS) technology allows for rapid and portable analysis of bioreactor conditions enabling detection of sterility failure in hours rather than days. Draper's innovative manufacturing technologies and approaches reduce cost, shorten the timeline for production, advance domestic competitiveness and reduce supply chain risk of biologics and cellular and gene therapies.
